We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA Warns Of Possible Birth Defects From Dolutegravir HIV Drug

(May 22, 2018, 11:01 AM EDT) -- SILVER SPRING, Md. — The Food and Drug Administration on May 18 issued a drug safety communication that the HIV drug dolutegravir, sold as Tivicay, Juluca and Trimeq, has been associated...
To view the full article, register now.